Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.

IF 4.9 2区 医学 Q1 CLINICAL NEUROLOGY
Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros, Peixiong Yuan, Jenessa Johnston, Bashkim Kadriu, Todd D Gould, Carlos A Zarate
{"title":"Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.","authors":"Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros, Peixiong Yuan, Jenessa Johnston, Bashkim Kadriu, Todd D Gould, Carlos A Zarate","doi":"10.1016/j.jad.2024.12.036","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a determinant of the stress response system, and ketamine's efficacy in stressed mice exhibiting enhanced antidepressant responses. Here, we assessed the relationship between HPA axis, major depression features, and antidepressant response to ketamine in humans.</p><p><strong>Methods: </strong>We investigated 42 participants following medication washout with treatment-resistant depression who participated in a randomized, placebo-controlled, crossover trial receiving intravenous ketamine. Plasma levels of corticotropin-releasing factor (CRF), adrenocorticotropic hormone (ACTH), and cortisol were measured at baseline. Ketamine's antidepressant effects were assessed using the Montgomery-Asberg Depression Rating Scale.</p><p><strong>Results: </strong>We found that baseline HPA axis hormone levels did not significantly moderate the antidepressant effects of ketamine. However, a negative association was observed between ACTH and CRF levels and the overall duration of depressive episodes, suggesting potential biomarker implications. Also, a negative correlation between baseline depressive scores and age of onset was observed, suggesting that the severity of depression might be greater if it develops at a younger age, indicating more enduring stress on the brain and body.</p><p><strong>Discussion: </strong>Although we did not find a moderation effect of the plasma HPA axis hormones on the antidepressant effects of ketamine, moderation effects of the brain HPA axis hormones cannot be precluded and warrants further investigation. Importantly, our results implicate HPA axis components as potential biomarkers for the duration of depressive episodes.</p>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jad.2024.12.036","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a determinant of the stress response system, and ketamine's efficacy in stressed mice exhibiting enhanced antidepressant responses. Here, we assessed the relationship between HPA axis, major depression features, and antidepressant response to ketamine in humans.

Methods: We investigated 42 participants following medication washout with treatment-resistant depression who participated in a randomized, placebo-controlled, crossover trial receiving intravenous ketamine. Plasma levels of corticotropin-releasing factor (CRF), adrenocorticotropic hormone (ACTH), and cortisol were measured at baseline. Ketamine's antidepressant effects were assessed using the Montgomery-Asberg Depression Rating Scale.

Results: We found that baseline HPA axis hormone levels did not significantly moderate the antidepressant effects of ketamine. However, a negative association was observed between ACTH and CRF levels and the overall duration of depressive episodes, suggesting potential biomarker implications. Also, a negative correlation between baseline depressive scores and age of onset was observed, suggesting that the severity of depression might be greater if it develops at a younger age, indicating more enduring stress on the brain and body.

Discussion: Although we did not find a moderation effect of the plasma HPA axis hormones on the antidepressant effects of ketamine, moderation effects of the brain HPA axis hormones cannot be precluded and warrants further investigation. Importantly, our results implicate HPA axis components as potential biomarkers for the duration of depressive episodes.

背景:亚麻醉剂量的(R,S)-氯胺酮(氯胺酮)对抑郁症患者具有快速而强大的抗抑郁作用。然而,对氯胺酮的反应存在个体差异,目前氯胺酮治疗反应的生物标志物还不完全清楚。临床前证据表明,下丘脑-垂体-肾上腺(HPA)轴激活(应激反应系统的决定因素)与氯胺酮在应激小鼠中的疗效之间存在联系,应激小鼠表现出更强的抗抑郁反应。在此,我们评估了HPA轴、重度抑郁症特征和人类对氯胺酮的抗抑郁反应之间的关系:我们调查了42名药物冲洗后的难治性抑郁症患者,他们参加了一项随机、安慰剂对照、交叉试验,静脉注射氯胺酮。基线测定了促肾上腺皮质激素释放因子(CRF)、促肾上腺皮质激素(ACTH)和皮质醇的血浆水平。使用蒙哥马利-阿斯伯格抑郁评定量表评估氯胺酮的抗抑郁效果:结果:我们发现基线 HPA 轴激素水平对氯胺酮的抗抑郁作用没有明显的调节作用。然而,我们观察到促肾上腺皮质激素(ACTH)和促肾上腺皮质激素(CRF)水平与抑郁发作的总体持续时间呈负相关,这表明氯胺酮具有潜在的生物标志物意义。此外,我们还观察到基线抑郁评分与发病年龄之间存在负相关,这表明如果抑郁症发病年龄较小,其严重程度可能会更大,这表明大脑和身体承受的压力会更持久:讨论:虽然我们没有发现血浆HPA轴激素对氯胺酮抗抑郁作用的调节作用,但不能排除大脑HPA轴激素的调节作用,这值得进一步研究。重要的是,我们的研究结果表明,HPA轴激素是抑郁发作持续时间的潜在生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of affective disorders
Journal of affective disorders 医学-精神病学
CiteScore
10.90
自引率
6.10%
发文量
1319
审稿时长
9.3 weeks
期刊介绍: The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信